Abstract | INTRODUCTION: METHODS: Systematic review of EMBASE and PubMed databases performed according to PRISMA guidelines from inception to March 2020; meta-analysis performed by Peto's odds ratio for rare events. FINDINGS: Forty-five studies with different outcomes met the inclusion/exclusion criteria. The pooled prevalence (PP) of IgG anticardiolipin antibodies (aCL) positivity was greater in end-stage renal disease ( ESRD) than controls (20.2% vs. 2.6%, P = 0.001, I2 >80%; I2 = heterogeneity), particularly in hemodialysis patients (18.3% vs. 8%, I2 = 0%). The PP of lupus anticoagulant was greater in ESRD than controls (8.7% vs. 0.2%, P < 0.0001, I2 = 0%). The standardized mean difference of IgG aCL favored ESRD rather than controls (P < 0.0001, I2 =97%). The PP of fistula occlusion was greater in IgG aCL-positive patients than negative patients (39% vs. 27%, I2 =97%); the PP of IgG aCL positivity was greater in patients with fistula occlusion than without fistula occlusion (26.9% vs. 23.2%, P = 0.01, I2 =72%); the same applied to the PP of lupus anticoagulant positivity (23% vs. 0.3%, P < 0.0001, I2 = 0%). The standardized mean difference of IgG aCL favored fistula occlusion (P = 0.004, I2 = 91%). DISCUSSION:
|
Authors | Paul R J Ames, Mira Merashli, Tommaso Bucci, Daniele Pastori, Pasquale Pignatelli, Francesco Violi, Vincenzo Bellizzi, Alessia Arcaro, Fabrizio Gentile |
Journal | Hemodialysis international. International Symposium on Home Hemodialysis
(Hemodial Int)
Vol. 24
Issue 3
Pg. 383-396
(07 2020)
ISSN: 1542-4758 [Electronic] Canada |
PMID | 32524729
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review)
|
Copyright | © 2020 International Society for Hemodialysis. |
Chemical References |
- Antibodies, Antiphospholipid
|
Topics |
- Antibodies, Antiphospholipid
(metabolism)
- Humans
- Kidney Failure, Chronic
(complications)
- Renal Dialysis
(methods)
|